Evidence map›Paper›PMID 26851381›Full record

ReviewEuropean journal of cancer (Oxford, England : 1990)2016

Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.

M Giefing, M Wierzbicka, K Szyfter, J C Brenner, B J Braakhuis, R H Brakenhoff, C R Bradford, J A Sorensen, A Rinaldo, J P Rodrigo and 2 more

Open access · greenAbstract readReview
In one paragraph

Review in European journal of cancer (Oxford, England : 1990), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Oral cancer: changing the aim of the biopsy in the age of precision medicine. A review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2021
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 6 countries.

M GiefingInstitute of Human Genetics, Polish Academy of Sciences, Department of Cancer Genetics, 60-479, Poznan, Poland; Department of Otolaryngology and Laryngological Oncology, K. Marcinkowski University of Medical Sciences, 60-355, Poznan, Poland.
M WierzbickaDepartment of Otolaryngology and Laryngological Oncology, K. Marcinkowski University of Medical Sciences, 60-355, Poznan, Poland.
K SzyfterInstitute of Human Genetics, Polish Academy of Sciences, Department of Cancer Genetics, 60-479, Poznan, Poland; Department of Phoniatrics and Audiology, K. Marcinkowski University of Medical Sciences, 60-355, Poznan, Poland.
J C BrennerDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: chadbren@umich.edu.
B J BraakhuisDepartment of Otolaryngology - Head and Neck Surgery, VU University Medical Center, Amsterdam, the Netherlands.
R H BrakenhoffDepartment of Otolaryngology - Head and Neck Surgery, VU University Medical Center, Amsterdam, the Netherlands.
C R BradfordDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.
J A SorensenDepartment of Plastic Surgery, Odense University Hospital, Denmark.
A RinaldoUniversity of Udine School of Medicine, Udine, Italy.
J P RodrigoDepartament of Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.
R P TakesDepartment of Otolaryngology-Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
A FerlitoCoordinator of the International Head and Neck Scientific Group, Italy.
Amsterdam UMC Location Vrije Universiteit Amsterdam · NLUniversity of Michigan · USInstitute of Human Genetics · PLOdense University Hospital · DKPolish Academy of Sciences · PLPoznan University of Medical Sciences · PLRadboud University Medical Center · NLUniversidad de Oviedo · ESUniversity of Udine · IT

Funding

Dissecting Co-Dependent Pathways in Oral CancersU01DE025184 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRENNER, JOHN CHADWICK, CAREY, THOMAS E. · 2015 to 2018
$3.7M
Advanced Research Training in OtolaryngologyT32DC005356 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORFAS, GABRIEL · 2002 to 2021
$3.5M
NIDCD NIH HHS T32 DC005356NIDCR NIH HHS U01 DE025184NIDCR NIH HHS U01DE025184
6 · The paper itself

Abstract

Personalised medicine tumour boards, which leverage genomic data to improve clinical management, are becoming standard for the treatment of many cancers. This paper is designed as a primer to assist clinicians treating head and neck squamous cell carcinoma (HNSCC) patients with an understanding of the discovery and functional impact of recurrent genetic lesions that are likely to influence the management of this disease in the near future. This manuscript integrates genetic data from publicly available array comparative genome hybridization (aCGH) and next-generation sequencing genetics databases to identify the most common molecular alterations in HNSCC. The importance of these genetic discoveries is reviewed and how they may be incorporated into clinical care decisions is discussed. Considerations for the role of genetic stratification in the clinical management of head and neck cancer are maturing rapidly and can be improved by integrating data sets. This article is meant to summarise the discoveries made using multiple genomic platforms so that the head and neck cancer care provider can apply these discoveries to improve clinical care.

Indexed as

High-Throughput Nucleotide SequencingPrecision MedicineAnimalsAntineoplastic AgentsBiomarkers, TumorCarcinoma, Squamous CellComparative Genomic HybridizationGenetic Predisposition to DiseaseGenetic TestingHead and Neck NeoplasmsHumansPatient SelectionPhenotypePredictive Value of TestsSquamous Cell Carcinoma of Head and NeckTreatment OutcomeAntineoplastic AgentsBiomarkers, TumorGenetic complexityHNSCCNGS technologyPersonalised medicineTarget genesTumour heterogeneity

Identifiers

PMID26851381
PMCPMC4761501
OpenAlexW2258562816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.